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Background: BRAF inhibitors such as vemurafenib are a new family of biological drugs, recently available to treat
metastatic malignant melanoma.
Methods: We present the case of a 38-year-old man affected by metastatic melanoma who had been under
treatment with vemurafenib for a few days. The patient suffered from sudden onset of abdominal pain due to
intra-abdominal hemorrhage with profuse hemoperitoneum. An emergency abdominal sonography confirmed the
clinical suspicion of a splenic rupture.
Results: The intraoperative finding was hemoperitoneum due to splenic two-step rupture and splenectomy was
therefore performed. Histopathology confirmed splenic hematoma and capsule laceration, in the absence of
metastasis.
Conclusions: This report describes the occurrence of a previously unreported adverse event in a patient with stage
IV melanoma receiving vemurafenib.
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Atraumatic splenic rupture (ASR) is a rare pathology
that can be idiopathic (7%) or pathological (93%) in na-
ture [1]. While in the first group there are no abnormal
histopathological findings, in the second one several
etiological factors can be identified, including neoplastic
(30%), infectious (27%), inflammatory non-infectious
(20%), drug- or treatment-related (9%), and mechanical
disorders (6%) [1].
ASR is an often unrecognized and potentially fatal
cause of acute abdomen development; it should be rou-
tinely considered in the differential diagnosis of such
pathology and when present promptly managed, at best
with laparotomic approach [2]. The commonest causes
of this rare pathology are: malignant hematological dis-
orders (16%) such as acute leukemia and non-Hodgkin’s
lymphoma; viral infections (15%) as infectious mono-
nucleosis and cytomegalovirus infection; and local* Correspondence: djdesi85@hotmail.it
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reproduction in any medium, provided the orinflammatory and neoplastic disorders (11%) such as
acute and chronic pancreatitis. Splenomegaly is a com-
mon feature, affecting 55% of patients. There is a male
gender prevalence of 2:1, with a mean age of 45 years,
(median 45, range 18–86 years). The overall ASR-related
mortality rate is 12% [1].
Although, nowadays, the laparoscopic approach is the
routine procedure for various diseases requiring elective
splenectomy, in emergency cases laparotomy still retains
its effectiveness, first and foremost with regard to
patients with unstable hemodynamic conditions.Case presentation
In September 2011, a 38-year-old man was admitted in
urgency regimen to our department because of a moder-
ate left flank pain starting 6 h before hospital admission.
The patient also presented vomiting and diffuse abdom-
inal tenderness. Minor discomfort had been present in
the left flank for a few days. The patient had a 3-year
history of melanoma, starting in November 2008 with
the removal of a forehead superficial spreading melan-
oma, 7 mm in diameter, Breslow thickness beingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Abdominal ultrasonography showing the spleen
rupture with hemoperitoneum.
Figure 2 Section of spleen in which can be seen laceration of
the capsule due to rupture in two times.
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the surrounding tissue, without ulceration or regression.
Only radicalization of local excision and follow-up were
required according to the initial staging; sentinel node
biopsy was therefore not performed.
In June 2011, 31 months after primary tumor excision,
and 3 months before the episode of acute abdominal
pain, the patient underwent an emergency orchiectomy
because of the onset of acute scrotal swelling, with a
pathologic diagnosis of metastatic melanoma to the testis
(with an immunohistochemical profile positive for HMB-
45, S-100, MART-1, and negative for pancytokeratin and
inhibin). At that time, PET and CT scans showed several
possible metastases, in soft tissues, gastro-intestinal tract,
lungs, and brain; biopsies of masseter muscle, stomach,
and duodenum confirmed the diagnosis.
The patient, after testing positive on screening for MO
255515 protein, was recruited to an experimental proto-
col using BRAF inhibitors and thus received a first cycle
of therapy with vemurafenib at an oral dose of 960 mg
twice daily. He did not undergo combined therapy with
cytotoxic drugs, but received vemurafenib alone. Such
experimental protocol was part of a compassionate care
strategy and foresaw specific exclusion criteria, such as
the presence of second malignancies, renal failure and
diabetes mellitus, co-morbidities that our patient did not
have. The acute abdominal event occurred 12 days after
starting treatment, when the patient had assumed a total
cumulative dose of about 23 g.
On admission the patient was pale and suffering, and
his vital parameters were as follows: oxygen saturation
100%; heart rate 90 bpm, temperature 36.5°C, blood
pressure 90/45 mmHg. His medical history was other-
wise negative, and no trauma or accident had been pre-
viously reported. An abdominal examination showed
diffuse pain and peritoneal fluid was noticed at percus-
sion; a nasogastric tube was placed without detecting
gastric retention and a urinary catheterization showed
oliguria. A complete blood count showed moderate
leukocytosis (13.67 WBC x103) and anemia (RBC 3.42
x106, Hb 10.4 g/dL, Ht 30.8%). An immediate abdominal
sonography confirmed the clinical suspicion of spontan-
eous rupture of the spleen with massive hemoperito-
neum (Figure 1). The patient immediately underwent an
emergency laparotomy. Intraoperative findings have
been massive hemoperitoneum (approximately 3 L of
blood and coagula) due to a two-step rupture of the
spleen, with subsequent subcapsular hematoma and
complete decortication, that required a splenectomy;
splenic size was within the normal range (Figure 2).
Some suspected metastatic nodes were removed from
the great omentum; histopathology confirmed the meta-
static nature of the omental nodes while the spleen was
decorticated in the absence of metastases.The postoperative course was complicated by the
onset, on the fourth day, of partial thrombosis of the
great saphenous vein; the diagnosis was confirmed by
sonography and a therapy of 40 mg low molecular
weight heparin (LMWH) (ClexaneW, Aventis Pharma,
Bad Soden, Germany; 0.4 mL prefilled syringes) sub-
cutaneously administered twice daily was undertaken.
The abdominal drainage was removed 5 days after the
operation, and the patient was discharged on the fol-
lowing day.
Castellani et al. World Journal of Surgical Oncology 2012, 10:155 Page 3 of 5
http://www.wjso.com/content/10/1/155Discussions
Melanoma is the deadliest form of skin cancer; its inci-
dence has been increasing continuously and over 40,000
people die of this disease each year worldwide [3]. The
estimated number of new cases of melanoma in 2010 in
the United States was 68,130, of which 57% affected
males and 43% females. In the same period, the esti-
mated deaths caused by this pathology were 8,700 (65%
males and 35% females) [4].
The disease presents genetically and clinically distinct
subgroups that could indicate the need of patient-
specific management strategies [5]. For example, head
and neck mucosal malignant melanomas behave much
more aggressively than limb or trunk tumors and their
prognostic markers have not yet been fully elucidated
[6]. The majority of metastases appears within 3 years
from the diagnosis of primary melanoma [7]. Primary
melanoma metastasizes most frequently to lymph nodes
and lungs (about 70%). Less common sites of metastasis
are liver (58%), brain (54%), bones (48%), adrenal glands
(46%), and gastrointestinal tract (43%). Among this
group, small intestine and spleen are affected in 36.5%
and 30.6% of cases, respectively [7]. The 1-year survival
rate for patients with systemic metastasis from cutane-
ous melanoma ranged from 40% to 60% in the American
Joint Committee on Cancer (AJCC) Melanoma Staging
Database [8]. Our patient had a stage IV melanoma, and,
therefore, an extremely poor prognosis with median sur-
vival ranging from 6 to 18 months after diagnosis [9]
and a 5-year survival rate of less than 5% [10-12].
Melanoma treatment has experienced a rapid change
in recent years through recent discoveries of target ther-
apies and immunotherapeutic antibodies. With the con-
tinuous progress of research, prolonged therapeutic
success may be achieved through the tailored use of mo-
lecular markers and immunotherapies in sequential or
combinatorial methods [13,14]. Advanced melanomas
often have multiple genetic defects affecting several bio-
chemical pathways. Somatic point mutations in RAF
occur in approximately 8% of human tumors, most fre-
quently in melanoma, colorectal, and thyroid cancers
[4,14,15]. The targeting of this single oncogenic alter-
ation with specific inhibitory nucleic acids or chemical
RAF inhibitors in melanoma cell lines showed growth
arrest and induction of apoptosis [16,17].
Although melanoma metastases have been found to
contain thousands of mutations, the V600E BRAF muta-
tion is clearly a driver of the neoplastic phenotype and is
present in approximately 50% of melanomas [5,18]. The
discovery of activating mutations (V600E) in the BRAF
kinase encouraged the development of compounds to in-
hibit aberrant BRAF activity [5]. Vemurafenib (also
known as PLX4032, RG7204, or RO5185426) marketed
as Zelboraf is a BRAF enzyme inhibitor developed byPlexxikon (Berkeley, CA, USA, now part of the Daiichi
Sankyo Group) and Roche [15]. PLX4032 was recently
observed to increase median overall survival in meta-
static melanoma. However, resistance through up-
regulation of receptors or by activating mutations in
oncogenic signaling and alternative enzymes is proving
to be an emerging problem [3]. The comparison be-
tween vemurafenib and conventional treatment with
dacarbazine led to encouraging results regarding 6-
month survival, which was 84% in the vemurafenib
group and 64% in the dacarbazine group. The risk of ei-
ther death or disease progression was also reduced in
the vemurafenib group [9]. In summary, these studies re-
veal that, for the first time, several immunotherapeutic
and targeted agents are yielding some clinical responses
and improvements in overall survival in patients with
unresectable stage III and IV melanoma [3]. In patients
with metastatic melanoma featuring BRAF V600E muta-
tion, phase 1 and 2 clinical trials of the BRAF kinase in-
hibitor vemurafenib (PLX4032) have shown response
rates of more than 50% [9].
Selective BRAF inhibitors show good tolerability with
infrequent severe toxicities. Among the common adverse
events associated with vemurafenib are skin changes
50% to 70% (rash, alopecia, keratoacanthoma or
squamous-cell carcinoma, photosensitivity), fatigue, and
arthralgia 30% to 50%, diarrhea 10% to 30%, and nausea
10% to 20% [16]. About 15% to 30% of patients treated
with type I BRAF inhibitors, such as vemurafenib, de-
velop squamous-cell carcinomas and keratoacanthomas.
These non-melanoma skin cancers are not deadly, but
they can become dangerous, when they rarely become
metastatic [19]. Squamous cell tumors from patients
treated with BRAF inhibitors have a distinct mutational
profile. A higher frequency of activating RAS mutations
was found in tumors from patients treated with vemura-
fenib (about 60%) vs. sporadic cases (range between 3%
and 30%) [20]. Vemurafenib alone does not increase the
number of tumors; it just decreases their latency by pro-
moting pre-existent mutations. This is evidenced by the
early appearance of lesions (within the first few weeks)
after assumption of vemurafenib, and only in a subset of
patients [21]. Therefore, testing the RAS status should
be useful in patients who undergo treatment with BRAF
inhibitors. Assuming that concomitant administration of
MEK inhibitors can stop vemurafenib-induced acceler-
ation of tumor growth in patients with RAS mutation, it
may be possible to develop a new generation of BRAF
inhibitors [22-24].
Another emerging problem is the resistance to BRAF
inhibitors that develops within months [25].
Recent studies suggest that it could depend on
tyrosine-kinase receptors (like PDGFR and IGFR-1)
[26,27]. Inhibitors of c-Kit and mitogen-activated protein
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nomas, and MEK inhibitors are now being examined as
a strategy to overcome BRAF inhibitor resistance [27].
ASR is uncommon but fatal if untreated. Its diagnosis
should not be missed or delayed because of low clinical
suspicion; in contrast it should be routinely considered
in the differential diagnosis of acute surgical abdomen
and of a wide range of medical conditions [28]. Various
hypotheses could be advanced concerning the possible
correlations between underlying disease, drug therapy,
and acute complications. The possibility that a link be-
tween cancer and spontaneous splenic rupture exists in
the absence of splenic metastasis or chemotherapy has
been suggested for a long time, and the reasons are to
be found in a hypercoagulable state secondary to the
underlying malignancy [29-32]. Furthermore, the possi-
bility of splenic rupture without a previous trauma in
patients under treatment for abdominal manifestations
of metastatic cancer has already been described, but me-
tastases were assumed to be the cause [33,34]. Another
possible cause might be found in alterations of angiogen-
esis pathways; BRAFV600E-dependent VEGF production
has been suggested as angiogenetic promoter mechan-
ism [35]. Oncogenic BRAF V600E mutation seems to
enhance the expression of several proangiogenic and
proinflammatory molecules, including VEGF-A [36].
BRAF binds to and is downstream from the main effec-
tors of KRAS, whose activating mutations are believed
to support the chaotic tumor vascularity, by up-
regulating the transcription of several angiogenic indu-
cers, including VEGF-A [37]. This might have caused
splenic parenchyma fragility, resulting in a greater ten-
dency to a spontaneous or minor trauma-related rup-
ture; in fact, whether and to what measure BRAF
regulates and alters angiogenesis is still unclear.Conclusions
As shown by clinical data, we can assume a relationship,
which is currently not verifiable, between the intake of
BRAF inhibitors and spontaneous rupture of the spleen;
also superficial venous thrombosis in the postoperative
course has been reported. With this report we intend to
comment on an unusual event, namely the spontaneous
rupture of the spleen occurred in a patient with stage IV
melanoma under treatment with vemurafenib, in the ab-
sence of neoplastic involvement of the spleen, spleno-
megaly, or major alterations of coagulation.Consent
Written informed consent was obtained from the patient
for publication of this manuscript and any accompany-
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